Blood Screening Market Share

Blood Screening Market Overview

Blood Screening Market Size was valued at USD 2.70 Billion in 2023. The Global Blood Screening industry is projected to grow from USD 3.40 Billion in 2024 to USD 5.60 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.20% during the forecast period (2024 - 2032).

Increasing blood donations and transfusion-related screenings, the prevalence of infectious diseases, the growing geriatric population, and awareness regarding transfusion-transmitted illnesses are the key market drivers boosting blood screening market share.

 Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

The important factors driving the market share of blood screening are the rise in blood donations and the implementation of screenings linked to transfusion, the increasing frequency of infectious diseases, the expanding population of elderly individuals, and the heightened awareness around disorders transmitted by transfusion. The market's quick expansion may be attributed to many significant causes, namely the upward trend in blood donations, the rising frequency of infectious illnesses, and the proactive involvement of governmental entities.

The market is being driven by the growing awareness of healthcare and the increasing acceptance of nucleic acid amplification tests (NAT). Furthermore, the market expansion has been propelled by the implementation of healthcare programs by governmental bodies, the augmentation of healthcare spending, and the improvements in blood screening technologies. Nevertheless, the expansion of the market is hindered by many issues including rigorous regulatory clearances, a scarcity of experienced workforce, and elevated operational expenses. The worldwide blood screening market is anticipated to see profitable potential with the use of pathogen reduction technologies and advancements in microbiology screening and multiplexing techniques.

In August 2023, C2N Diagnostics, a developer of a blood test for Alzheimer's disease, has unveiled an updated iteration of their beta amyloid protein screener. With increasing public optimism over potential cures for Alzheimer's disease, the company is preparing for a widespread implementation of the test across the nation. The clinical care exam functions as a follow-up to the PrecivityAD test, which was initially introduced around three years ago. Known as PrecivityAD2, this method utilizes mass spectrometry to identify trace amounts of certain proteins that have migrated from amyloid plaques in the brain to the circulation.

Blood Screening Market Trends

• 
  

  Emergence of automated molecular platforms for blood screening to propel market growth

  
  

Automated molecular platforms for blood screening are becoming a popular strategy among leading market players, fueling market growth. Blood screening tests aim to ensure the security of donated blood units and to find any signs of transmissible transfusion infections (TTIs) in the blood. The transition from manual to automated screening platforms has been critical in identifying contagious transfusion infections (TTIs) in blood samples. In the transfusion screening process, growing automation is anticipated to reduce human error. These screening tests generally impact most medical decisions in blood banks and hospitals.

For instance, F. Hoffmann-La Roche Ltd. confirmed the CE-IVD launch of "cobas" in December 2019, which is intended to be utilized for blood donation screening and locates the Zika virus in human plasma. As a result, the adoption of these automated molecular platforms in blood donation facilities has increased due to the introduction of these platforms by key players. This will drive the growth of the blood screening market CAGR over the forecasted period. Other key factors boosting the development of the Blood Screening Market revenue include increasing blood donations and blood donors, raising awareness of the safety of donated blood, growing the prevalence of infectious diseases, and various government initiatives. The number of blood donations worldwide in 2022 is estimated to be around 118.5 million. Additionally, the WHO suggests that blood donations be screened for illnesses before use, including hepatitis B, syphilis, and other sexually transmitted diseases (STDs).

Blood Screening Market Segment Insights

Blood Screening Technology Insights

Based on materials, the Blood Screening Market segmentation includes nucleic acid amplification tests, enzyme-linked immunosorbent assay, and next-generation sequencing. The nucleic acid amplification tests segment held the majority share in 2022, contributing to around ~45-47% of the Blood Screening Market revenue. The advanced benefits of nucleic acid amplification test technology, such as high specificity and sensitivity for early detection, account for most of the share. The test detects nucleic acid sooner than other screening methods, narrowing the window period for HBV, HCV, and HIV infections. In addition, its largest share is also influenced by the technology's widespread use in hospitals, clinical labs, and blood banks. Moreover, the widespread adoption of this technology in developing and emerging markets creates new avenues for the segment's expansion.

Figure 1: Global Blood Screening Market, by Technology, 2022 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

Blood Screening Product & Services Insights

Applications have bifurcated the Blood Screening Market data into reagents and instruments. The reagents segment dominated the market in 2022 and is anticipated to be the faster-growing segment in the forecast period 2024-2032. Reagents, a recurring expense, are widely used in immunoassays and molecular tests. Factors such as increased blood donations and transfusion-related screenings, as well as the increasing prevalence of infectious diseases, are driving the growth of this segment. Additionally, the COVID-19 outbreak has increased serological testing, which has helped grow this market segment. These kits have uses in clinical chemistry, polymerase chain reaction (PCR), diabetes, in vitro and molecular diagnostics, test strips, and the detection of illicit drugs. Reagents and kits are also used privately or at the Point of Care (POC) for DNA lineage analysis, glucose strips, and at-home pregnancy tests.

Blood Screening End User Insights

Based on End Users, the global Blood Screening Market segmentation has been divided into hospitals, clinics, and others. Hospitals held the most prominent segment share in 2022 due to the increasing frequency of blood transfusion procedures in these settings. Many hospitals worldwide use patient blood management programs to help with transfusion, and screening practices, primarily to improve patient outcomes, cut costs and conserve blood units. Moreover, growing collaborations between blood centers and hospitals fuel the adoption of blood screening tests in these settings, driving the blood screening market growth throughout the forecast period.

In December 2022, PredOmix introduced a novel blood test called OncoVeryx-F, which has a unique capability to accurately detect early-stage malignancies in women with a remarkable accuracy rate of 98%. Utilizing cutting-edge metabolomics technology in conjunction with artificial intelligence (AI), this novel advancement will facilitate the detection of early-stage malignancies through screening processes. The screening method, specifically tailored for the female population, effectively and precisely detects cancer at an early stage, prior to the initiation of tumor formation. The patented technology known as OncoVeryx-F integrates metabolomics and artificial intelligence methodologies for the purpose of early cancer detection.

July 2023: Quest Diagnostics has recently introduced the inaugural direct-to-consumer blood test designed to identify atypical levels of beta amyloid, a crucial protein associated with Alzheimer's disease that may manifest years prior to the onset of dementia symptoms. The news is a result of the recent regulatory clearance in the United States of Leqembi, a pharmaceutical product developed by Eisai in collaboration with Biogen. Leqembi is designed to eliminate amyloid from the brain and has demonstrated efficacy in slowing the progression of Alzheimer's disease in individuals in the early stages of the condition.

Blood Screening Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Blood Screening market accounted for USD 1.14 billion in 2022 and is likely to exhibit a significant CAGR growth over the study period. The region's largest share is mainly attributed to rising blood transfusion-related screenings, increasing infectious disease prevalence, an aging population, the need for early disease detection and monitoring, rising healthcare expenditure, and the growing adoption of technologically advanced blood screening technologies. This region's dominance is further attributed to increased blood donors, widespread implementation of blood screening procedures, and improved patient affordability.

Further, the major countries studied in the global market report are the U.S., Germany, Canada, France, the UK, Spain, Italy, Japan, India, Australia, China, South Korea, and Brazil.

Figure 3: BLOOD SCREENING MARKET SHARE BY REGION 2022 (%)

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

The second-largest market share belongs to the European blood screening market, where respiratory illnesses and cancer are becoming more common. Rising government support and increased private-sector investment in the research and development of various blood screening tests are driving revenue growth in this region. For instance, F. Hoffmann-La Roche Ltd. introduced the Cobas Zika test for Cobas 6800/8800 Systems on December 16, 2019. The Cobas Zika test is designed to screen blood donations in Europe for Zika virus infection by finding RNA in human plasma samples. In addition, the European Union has made blood screening for HCV, HBV, HIV, parvovirus-19, and other viruses mandatory. Further, the German blood screening market held the largest market share, and the UK blood screening market was the fastest-growing market in the European region.

The Asia-Pacific Blood Screening Market is projected to grow at the fastest CAGR from 2024 to 2032, owing to rising patient affordability and key industry players' increased focus on emerging markets. Japan, India, China, Singapore, and Australia contribute significantly to the market in the Asia Pacific region. Moreover, China’s blood screening market held the largest market share, and the Indian blood screening market was the fastest-growing market in the Asia-Pacific region.

India's blood screening market differs from other Asia Pacific nations like China and Japan as of laxer regulatory requirements and the importation of the necessary equipment and materials. Expanded investments by private and international entities, which may help offer practical tests at lower prices, are expected to lead to significant growth in the Indian blood screening industry. India's well-connected network of clinical laboratories and healthcare facilities is accelerating the adoption of blood screening methods.

Blood Screening Key Market Players & Competitive Insights

The competitive landscape is semi-consolidated, with several domestic and international blood screening industry players operating globally. Major market players are investing heavily in research and development to develop more innovative and advanced techniques that minimize turnaround time and improve the effectiveness and accuracy of crossmatch screening. Key players use various market development strategies, including investing in adapting cutting-edge techniques, launching new technologies, mergers & acquisitions, and regional expansion to capture the largest share of global revenue.

Blood screening industry competitors must provide cost-effective products and services to develop and sustain in an intensely challenging and rising global market environment. The blood screening market major players, such as BioMerieux, Siemens Healthineers, Thermo Fisher Scientific Inc, and others, are working to increase industry demand by investing in research and development activities to ensure constant innovation. The global blood screening industry has recently provided some of the most substantial advantages to reagents and instruments.

Roche Diagnostics (Switzerland) is a company that provides diagnostic system solutions for hospitals, clinics, laboratories, and doctors' offices. The company creates, manufactures, and supports in-vitro diagnostic and bioanalytical instruments and software systems. It also provides test systems, molecular diagnostic reagents, blood screening products, diagnostic analysis systems, and workflow solutions. Blood glucose meters and point-of-care testing equipment are among its primary offerings. The company offers services and products to commercial diagnostic laboratories, hospitals, researchers, healthcare professionals, and pharmacists. Roche Diagnostics (Switzerland) purchased TIB Molbiol Group (Germany) in September 2021. This acquisition will broaden Roche's portfolio of molecular diagnostics solutions, including assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Also, Becton, Dickinson, and Company, or BD, is a multinational clinical technology company based in the United States that produces and distributes medical devices, indicator systems, and reagents. Additionally, in certain regions, BD offers consulting and analytics services. In March 2020, B.D. announced the launch of a singular blood screening test that can identify antibodies in blood to confirm current or previous COVID-19 exposure in less than 15 minutes.

Key Companies in the blood screening market include

• BioMerieux


• Bio-Rad Laboratories Inc


• Siemens Healthineers


• Ortho Clinical Diagnostics Inc


• Thermo Fisher Scientific Inc

Blood Screening Industry Developments

June 2021: Grail, an American pharmaceutical and biotechnology company, has announced the release of the Galleri blood screening test, an advanced multi-cancer screening diagnostic that can detect the presence of multiple cancers. This test will assist the company in screening approximately 50 million people after its launch to obtain full FDA approval by 2023.

May 2021: Tzar Labs, a molecular diagnostics company, and Epigeneres Biotechnology have announced the development of cancer tests for early detection. This test, which will be available by the end of 2023, will assist in determining the various stages of the disease. The company's accuracy rates for cancer screening tests are very high, and it has demonstrated results for all forms of cancer.

October 2020: Siemens Healthineers has announced the availability of its laboratory-based total immunoglobulin test1 for identifying SARS-CoV-2 IgM and IgG immunoglobulin in the blood throughout the world. The ability to identify patients who have an adaptive immune response is made possible by the complete antibody test.

Blood Screening Market Segmentation

Blood Screening Technology Outlook

• Nucleic Acid Amplification Test


• Enzyme-Linked Immunosorbent Assay


• Next-Generation Sequencing

Blood Screening Product & Services Outlook

• Reagents


• Instrument

Blood Screening End User Outlook

• Hospitals


• Clinics


• Others

Blood Screening Regional Outlook

• 
  
  Middle East
  
  


• 
  
  Africa
  
  


• 
  
  Latin America